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SUMMARY  
Aim: To characterize ticagrelor exposure-response relationship for platelet inhibition in 
patients with stable coronary artery disease (CAD) and a history of myocardial infarction 
(MI), using non-linear mixed effects modelling and simulation. 
Methods: Platelet function data were integrated with plasma concentration data of ticagrelor 
and its active metabolite AR-C1249010XX in a population pharmacokinetic and 
pharmacodynamic (PK/PD) model, based on two clinical studies. In the ONSET/OFFSET 
study, PK and platelet function were assessed in 123 CAD patients receiving placebo, 
ticagrelor (180 mg followed by 90 mg twice daily) or clopidogrel (600 mg followed by 75 mg 
once daily). In the PEGASUS-TIMI 54 platelet function substudy, PK and platelet function 
were assessed during maintenance dosing in 180 prior MI patients receiving placebo, 
ticagrelor 60 mg or ticagrelor 90 mg twice daily.  
Results: Platelet inhibition by ticagrelor was described by a sigmoidal Emax model. On 
average, half maximal inhibition was reached at ticagrelor concentrations of 116 (RSE: 5.3%) 
  
This article is protected by copyright. All rights reserved. 
nmol/L. Simulations showed that near maximal platelet inhibition is achieved with both 
ticagrelor 60 and 90 mg twice daily. At simulated lower doses, platelet inhibition is overall 
reduced, more variable between patients, and show greater peak-to-trough variability. 
Ticagrelor antiplatelet response was similar between the studied patient populations. 
Conclusions: In patients with stable CAD or a history of MI, near maximal platelet inhibition 
is achieved with both ticagrelor 60 and 90 mg twice daily. At modeled doses below 60mg, the 
response is overall reduced, more variable between patients, and patients will display greater 
peak-to-trough variability.  
 
WHAT IS KNOWN ABOUT THIS SUBJECT? 
x Ticagrelor is an oral P2Y12 receptor antagonist for prevention of cardiovascular events 
in acute coronary syndrome (ACS) or prior myocardial infarction (MI) patients.  
x High platelet inhibition may explain superior efficacy of ticagrelor versus clopidogrel 
in ACS patients, and similar efficacy of ticagrelor 60 and 90 mg in prior MI patients. 
WHAT THIS STUDY ADDS?  
x We describe the platelet inhibition time course and ticagrelor exposure relationship 
and predict the dose-response relationship in stable coronary artery and prior MI 
patients. 
x Reductions of the currently used ticagrelor doses 60 and 90 mg twice daily to 45 mg 
or lower may pose a risk of high platelet reactivity. 
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INTRODUCTION 
Ticagrelor (180 mg loading dose followed by 90 mg twice daily), in combination with low 
dose ASA, is used for the prevention of cardiovascular (CV) death, myocardial infarction 
(MI) and stroke in patients with acute coronary syndromes (ACS), based on the results of the 
PLATelet inhibition and patient Outcomes (PLATO) study [1]. Following the PEGASUS-
TIMI 54 study ticagrelor 60 mg twice daily, in combination with ASA, is also used for the 
long-term prevention of adverse CV events in patients with a history of MI [2]. 
Dose-dependent platelet inhibition has been demonstrated in healthy subjects receiving single 
doses of ticagrelor 30 to 400 mg [3], and 50 to 300 mg twice daily provides a consistently 
higher and more sustained platelet inhibition compared with ticagrelor 100 to 600 mg once 
daily [4]. A rapid onset and high degree of platelet inhibition was seen with ticagrelor in 
patients with stable coronary artery disease (CAD) in the ONSET/OFFSET study [5]. The 
inhibition was sustained during the maintenance phase and normalized platelet function was 
achieved within 120 hours after last dose.  
The pharmacokinetic (PK) profile of ticagrelor and its active, and similar potent [3], 
metabolite AR-C124910XX have been evaluated in healthy subjects as well as in patients 
with CAD, including stable atherosclerotic disease [8,9], ACS [10] and patients with a history 
of MI [11]. Although the platelet response to ticagrelor has been measured in several studies, 
a detailed quantitative model-based description of the longitudinal relationship between 
systemic ticagrelor exposure and platelet inhibition has not been previously published. The 
objective of this population pharmacokinetic/pharmacodynamic (PK/PD) analysis was to 
mathematically characterize the ticagrelor dose-concentration-response relationship by non-
linear mixed effects modelling, using data from the ONSET/OFFSET study and the 
PEGASUS-TIMI 54 platelet function substudy.  
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METHODS 
Clinical studies and data 
The present work is based on clinical data from the ONSET/OFFSET (Funded by 
AstraZeneca, NCT00528411) [5] and the PEGASUS-TIMI 54 study (Funded by 
AstraZeneca; NCT01225562) [2]. All subjects in both studies provided written informed 
consent, and the studies were approved by an Independent Ethics Committee and performed 
in accordance with guidelines established by the Declaration of Helsinki. 
ONSET/OFFSET study 
In the ONSET/OFFSET study [5], a total of 123 mainly white (88%) stable CAD patients 
were randomized to receive ticagrelor 90 mg twice daily following a 180 mg loading dose 
(n=57), clopidogrel 75 mg once daily following a 600 mg loading dose (n=54) or placebo 
(n=12) for approximately 6 weeks. All patients received acetylsalicylic acid (ASA) 75-100mg 
once daily. Ticagrelor and AR-C124910XX plasma concentrations were measured at pre-
dose and 0.5, 1, 2, 4, 8 and 24 hours after the first dose as well as at pre-dose and 2, 4, 8, 24 
and 48 hours after the last dose. Platelet function was measured at pre-dose and 2, 8 and 24 
hours after the first dose as well as at pre-dose and 8, 24, 48 hours, 5 and 10 days after the 
last dose.  In total, there were 648 ticagrelor and 648 AR-C124910XX plasma concentration 
measurements (including measurements below LOQ) and 608 platelet function measurements 
(including 103 from placebo-treated patients) from the ONSET/OFFSET study included in 
the model-based PK/PD analysis, see Table 1. The observed clopidogrel platelet function data 
(487 measurements) were summarized and compared with the model-based ticagrelor 
predictions. 
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PEGASUS-TIMI 54 platelet function substudy 
The PEGASUS-TIMI 54 study [2] included 1161 patients with a history of MI at 1 to 3 years 
prior to enrolment and at high risk of an atherothrombotic event. A total of 180 patients from 
the PEGASUS-TIMI 54 study, mainly white (93%) took part in a platelet function substudy 
[12] conducted at four centres: three in the United Kingdom (Sheffield, Rotherham and 
Nottingham) and one in the United States (Jacksonville, Florida). Patients were randomized 
to receive placebo (n=64), ticagrelor 60 mg twice daily (n=58) or ticagrelor 90 mg twice 
daily (n=58), and all patients received acetylsalicylic acid (ASA) 75-150 mg once daily. 
Ticagrelor and AR-C124910XX plasma concentrations and platelet function were measured 
at pre-dose and 2 hours post-dose after at least 4 months of study treatment. 113 ticagrelor- 
and 64 placebo-treated patients had observed data on both platelet inhibition and ticagrelor 
plasma concentrations. In total, there were 223 ticagrelor and 224 AR-C124910XX plasma 
concentration measurements and 346 platelet function measurements (including 127 from 
placebo-treated patients) from the PEGASUS-TIMI 54 platelet function substudy included in 
the model-based PK/PD analyses, see Table 1. 
Pharmacokinetic and pharmacodynamic measurements assays 
Samples for determination of ticagrelor and AR-C124910XX plasma concentrations were 
analysed by York Bioanalytical Solutions (York Bioanalytical Solutions, York, UK ± 
ONSET/OFFSET study) and Covance (Covance Bioanalytical Services, Indianapolis, 
Indiana, USA ± PEGASUS-TIMI 54 study). Ticagrelor, AR-C124910XX and the deuterated 
internal standard D7-ZD6140 were isolated from human plasma using protein precipitation. 
After reversed-phase liquid chromatography of the extract, ticagrelor, AR-C124910XX and 
the internal standard were measured by atmospheric pressure chemical ionization (APCI) 
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mass spectrometry in negative mode. The analytical methods have a validated calibration 
range of 1.9 to 3820 nmol/L for ticagrelor and 5.2 to 2080 nmol/L for AR-C124910XX, 
XWLOL]LQJDȝ/VDPSOHDOLTXRWZLWKDYDOLGDWHGGLOXWLRQZLWKhuman plasma. All samples 
were analysed within the known stability period [13].  
 
Platelet function was measured as P2Y12 UHDFWLRQXQLWV358XVLQJWKH9HULI\1RZDVVD\
(formerly Accumetrics, now Accriva Diagnostics, San Diego, CA, USA) shown not to be 
influenced by aspirin treatment [14]. In addition to PRU, 9HULI\1RZ also reports a BASE 
channel value where platelets are activated via thrombin receptors (using protease activated 
receptor-1 and receptor-4 peptides). The BASE channel has in-vitro been shown to be 
insensitive to high level of P2Y12 inhibition motivating using the BASE channel 
measurement as a baseline PRU measurement in absence of a true baseline PRU 
measurement [15]. Moreover, BASE channel values in PEGASUS-TIMI 54 study were 
overall similar in the placebo (mean=264), clopidogrel(mean=256) and ticagrelor(mean=262) 
treated patients. As no baseline measurements were included in the PEGASUS-TIMI 54 
study, graphical display of % inhibition from baseline were reported for each group based on 
the BASE channel value. 
 
Population pharmacokinetic and pharmacodynamic model development 
A population PK/PD model describing the relationship between ticagrelor dose, plasma 
concentrations and platelet function was developed in NONMEM version 7.3.0, using first-
order conditional estimation with interaction [16]. R version 3.2.0 [17], PsN version 4.4.0 
[18] and nonmem2R version 0.1.8 [19] were used for model execution, data management and 
presentation of results. 
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Firstly, the population PK model was developed based on data from the ONSET/OFFSET 
study and the PEGASUS-TIMI 54 platelet function substudy. The plasma concentration-time 
profiles of ticagrelor and AR-C124910XX were jointly modelled, both described using two-
compartment disposition models with first-order absorption/formation and elimination. The 
fraction of ticagrelor metabolized to AR-C124910XX (Fm) was fixed to 0.22. PK parameters 
were tested for difference between stable CAD and prior MI patients if suggested by the data 
and or model diagnostic. Ticagrelor (<1%) and AR-C124910XX (3.3%) measurements after 
first dose below the respective lower limit of quantification were included in the analysis and 
modelled using the M3 method [20]. However, all PK measurements prior first dose in the 
ONSET/OFFSET study were below the lower limit of quantification and were excluded from 
the analysis. 
Subsequently, the PK/PD model was developed to characterize the concentration-response 
relationship between ticagrelor and platelet function based on data from the ONSET/OFFSET 
study and PEGASUS-TIMI 54 platelet function substudy. The PK/PD model was developed 
with fixed population PK parameters from the final PK but with individual parameters 
estimated simultaneously based on both PK and PD data using the PPP&D method [21]. 
Models using the model predicted ticagrelor or the sum of ticagrelor and AR-C124910XX 
(both have similar potency in inhibiting the P2Y12 receptor [3]) concentrations as the driver 
of the drug response were tested. Direct or indirect-response relationships with linear or non-
linear concentration-response functions were tested if suggested by the data. The absolute 
PRU values were used in the model development and hence no BASE channel data was used 
for modelling. The model-predicted PRU change from baseline was calculated to describe the 
extent of platelet inhibition. PRU data from the placebo patients were included in the model 
to enable description of the PRU baseline levels. It was tested if PRU baseline and the 
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response to ticagrelor (EC50 and/or Emax parameters) were different between stable CAD 
and prior MI patients.  
Between-subject-variability (BSV) was estimated for some of the PK and PD parameters 
using additive or exponential models. The residual errors for ticagrelor, AR-C124910XX and 
PRU were tested to be described by additive, proportional, or combined additive and 
proportional models.  
Model evaluation 
Model development was guided by precision of parameter estimates, graphical goodness-of-
fit assessments and changes in the NONMEM objective function value (OFV). The 
GLIIHUHQFHLQ2)9EHWZHHQWZRQHVWHGPRGHOVLVDSSUR[LPDWHO\Ȥ2-distributed, with degrees 
of freedom (df) equal to the difference in the number of model parameters. Based on this, the 
statistical significance for inclusion/exclusion of a model parameter can be judged. A 
significance level of 0.01, corresponding to a 6.64 change in OFV for 1 df, was used for 
discrimination among nested models and was used in the final backward elimination of 
different model parameters between stable CAD and prior MI patients. Visual predictive 
checks (VPC) were performed for key models. The observed data were graphically compared 
to model predictions based on 1000 simulated study datasets using the final model. 
Illustration of the model-predicted dose-response relationship 
The model-predicted dose-response relationship was illustrated based on simulations with the 
final population PK/PD model. The expected platelet inhibition from baseline was simulated 
at steady-state after repeated administration of placebo or ticagrelor 15, 30, 45, 60 or 90 mg 
twice daily in 1000 patients at pre-dose and 2 hours post-dose. 
Nomenclature of Targets and Ligands 
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Key protein targets and ligands in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS 
Guide to PHARMACOLOGY [22] and are permanently archived in the Concise Guide to 
PHARMACOLOGY 2017/18 [23]. 
RESULTS 
A total of 871 ticagrelor and 872 AR-C124910XX plasma concentration measurements and 
954 platelet measurements from the ONSET/OFFSET study and PEGASUS-TIMI 54 platelet 
function substudy were used in building the above described models. Further details on 
number of measurements and sampling times of measurements are presented in Table 1. 
Ticagrelor population PK model 
The ticagrelor and the AR-C124910XX plasma concentration-time data were adequately 
described by the two-compartment models. Describing the ticagrelor absorption by Erlang-
type absorption models [24] significantly lowered the OFV compared to a first-order 
absorption model. Absorption from the dosing compartment to the central compartment is in 
Erlang models linked via one or more transit compartments. In the present modelling the 
same transit rate (KTR) was used from the dose compartment to the first transit compartment, 
between transit compartments, and from the last transit compartment to the central 
compartment. Eight (8) transit compartments provided the lowest OFV among Erlang-type 
absorption models with 4 to 10 transit compartments. Introducing a lag-time to the 1-order 
absorption model did not provide a better model fit than the Erlang-type absorption model. 
Parameter estimates of the final PK model are presented in Table 1. Ticagrelor CL/F was 
estimated at 16.6 L/h with no statistically significant difference identified between the CAD 
and prior MI patients. However, adding a lag-time to the Erlang-type absorption model for 
the prior MI patients significantly lowered the OFV and provided better data to model 
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DJUHHPHQWLQ93&¶VBSV was included for ticagrelor CL/F, KTR, the relative bioavailability 
(Frel) and inter-compartment clearance (Q/F). For AR-C124910XX, BSV was included on 
CLm/F and the peripheral volume of distribution (Vpm/F). Separate proportional residual error 
models were used for ticagrelor and AR-C124910XX. There was good agreement between 
observed and predicted percentiles of the PK data (Figure 1). For a single loading dose of 
ticagrelor 180 mg, median Cmax was predicted at 2096 nmol/L. The average steady-state 
concentration (Css,av) was predicted at 576 nmol/L for ticagrelor 60 mg and at 864 nmol/L for 
ticagrelor 90 mg. 
Ticagrelor population PK/PD model for platelet function 
The platelet inhibition was seen to fluctuate over time with the varying ticagrelor plasma 
concentrations. The ticagrelor antiplatelet response was direct with no delay between plasma 
concentrations and platelet inhibition. The inhibitory effect of ticagrelor on platelets was best 
described by a direct-effects sigmoidal Emax model with a proportional drug response relative 
to the platelet function at baseline:  
ܴܲ ௧ܷ ൌ ܴܲ ௕ܷ௔௦௘௟௜௡௘ ൈ ቆ ? െܧ௠௔௫ ൈ ܥ௧ఊܧܥହ଴ఊ ൅ ܥ௧ఊቇ 
Parameter estimates of the final PK/PD model are presented in Table 2. The baseline PRU 
(PRUbaseline) was estimated lower in the PEGASUS-TIMI 54 study compared to the baseline 
in ONSET/OFFSET, estimated at 261 and 311 respectively. The drug potency parameter 
describing the ticagrelor concentration at half the maximal effect (EC50) was estimated at 116 
nmol/L and the maximal drug effect (Emax) parameter was estimated at 98.5%. The exponent 
ȖGHVFULELQJWKHVWHHSQHVVRIWKHH[SRVXUH-response relationship was estimated at 1.59. None 
of the EC50, Emax RU Ȗ GLIIHUHG EHWZHHQ WKH stable CAD and prior MI patient populations. 
Using the sum of ticagrelor and AR-C124910XX plasma concentration (opposed to only 
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ticagrelor) did not provide a significant improvement although with difference in OFV of 3.6 
in favour of using the sum of concentrations. For simplicity and greater usability, the model 
utilizing only ticagrelor for the drug effect was chosen. To provide adequate description of 
the variability, the additive residual error was described as a non-linear function increasing 
with increasing PRU levels. BSV was included for PRUbaseline, Emax and EC50, and covariance 
between PRUbaseline and EC50 was estimated. PRUbaseline was assumed normally distributed, 
Emax was assumed normally distributed on the logit transformed scale whereas EC50 was 
assumed log-normally distributed. There was good agreement between observed and 
predicted percentiles of the PRU data (Figure 2). The PK/PD model predicted that 80% 
median platelet inhibition (IQR: 66-86%), near the maximal response plateau, was on average 
reached at ticagrelor concentrations of 344 nmol/L (Figure 3), which is well below the herein 
predicted median ticagrelor Css,av for both ticagrelor 60 mg and ticagrelor 90 mg twice daily.  
Ticagrelor dose-response simulation for platelet inhibition  
The predicted dose-response relationship for ticagrelor-induced platelet inhibition is 
illustrated in Figure 4. Near maximal inhibition was achieved with both ticagrelor 60 mg and 
90 mg twice daily. The median maximal predicted PRU inhibition was 96%(IQR: 91-98%) 
and on average predicted to occur at 1.8 hours following a loading dose of ticagrelor 180 mg 
in CAD patients and at 2.4 hours in prior MI patients. For steady-state twice-daily drug-
administration, the median predicted PRU inhibition 2 hours post dose was 94% (IQR: 87-
97%) for ticagrelor 90 mg (92% for 60 mg, IQR: 83-96%) and trough PRU median inhibition 
12 hours post dose was 87%(IQR: 73-93%) for ticagrelor 90 mg (80% for 60 mg, IQR: 62-
90%).  The trough PRU inhibition variability was 28% for ticagrelor 60 mg and 22% for 
ticagrelor 90 mg, and the expected proportion of patients with inhibition below 70% 12 hours 
after dose was 34% and 22% for ticagrelor 60 mg and 90 mg, respectively. At lower doses 
the simulations showed decreased platelet inhibition but also more variable platelet inhibition 
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between patients and greater peak-to-trough variability. The trough PRU inhibition variability 
was 33% for ticagrelor 45 mg twice daily and 42% for ticagrelor 30 mg twice daily. The 
median inhibition ranged between 73% (IQR:53-86%) and 89% (IQR:78-95%) during a 
dosing interval with ticagrelor 45 mg twice daily and between 60% (IQR:39-77%) and 83% 
(IQR:68-91%) with ticagrelor 30 mg twice daily. The expected proportion of patients with 
inhibition below 70% 12 hours after dose was of 46% and 63% for ticagrelor 45 mg and 30 
mg twice daily respectively.  
DISCUSSION 
In this work, we have quantified the non-linear but direct relationship between systemic 
ticagrelor exposure and platelet inhibition in patients with stable CAD and patients with a 
history of MI. Using a model-based approach, the PK and PD data from the ONSET/OFFSET 
study [5] and PEGASUS-TIMI 54 platelet function substudy [12] could be integrated and 
jointly analysed. 
Platelet inhibition increased with increasing ticagrelor plasma concentrations and fluctuated 
with the ticagrelor levels over the dosing interval. There was no delay in the onset and offset 
of response, consistent with the reversible binding of ticagrelor to the P2Y12 receptor. A 
ticagrelor concentration of 344 nmol/L was predicted to translate into 80% median platelet 
inhibition (IQR: 66-86%), close to the maximal response plateau. As the median Css,av was 
higher, near maximal platelet inhibition was predicted to be consistently achieved with both 
ticagrelor 60 mg and 90 mg twice daily for both patient populations. There were relatively 
small fluctuations in platelet inhibition over the dosing interval, and even trough 
concentrations at pre-maintenance dosing with ticagrelor 60 mg were predicted to be high 
enough to generate close to full inhibition. This contrasts with the lower and more variable 
inhibition, in the steeper portion of the exposure-response curve, seen at therapeutic doses 
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with clopidogrel or with lower modelled doses of ticagrelor. In the ONSET/OFFSET study 
the median observed platelet inhibition at 8 hours after multiple doses (close to the expected 
time of maximal inhibition for clopidogrel), was 49% with clopidogrel 75 mg.  
The PEGASUS-TIMI 54 platelet function substudy data were in agreement with the 
ONSET/OFFSET data. The mean PRU baseline value was lower in the prior MI compared 
with the stable CAD patients, but the relative treatment response appeared consistent 
UHJDUGOHVVRIDSDWLHQW¶VEDVHOLQHOHYHO; there were overlapping exposure-response 
relationships between the populations. The PK/PD model predictions were in line with the 
observed data in the PEGASUS-TIMI 54 platelet function study where the platelet inhibition 
was similar between ticagrelor 60 mg and 90 mg, close to the maximal response, despite 37% 
lower ticagrelor concentrations for ticagrelor 60 mg both at pre-dose and 2 hours post-dose 
[12]. The PK/PD model predictions based on PEGASUS-TIMI 54 and ONSET/OFFSET data 
were further supported by the PLATO platelet function substudy [6]. The study showed high 
platelet inhibition both at pre-dose and 2-4 hours post-dose. The inhibition was slightly 
higher 2-4 hours post dose than at pre-dose with ticagrelor 90 mg, in accordance with the 
PK/PD simulations. 
  
The population PK of ticagrelor in patients with stable CAD was similar to that previously 
reported in ACS and prior MI patients. In this analysis, the mean ticagrelor CL/F was 16.6 
L/h in both CAD patients and patients with prior MI. In previous population PK analyses, the 
mean ticagrelor CL/F was 14 L/h for ACS patients in the PLATO study and 15.4 L/h for 
patients on ticagrelor 90 mg with a history of MI in the PEGASUS-TIMI 54 study [10, 11]. 
In the PEGASUS-TIMI 54 population PK analysis, CL/F of both ticagrelor and AR-
C124910XX were approximately 10% lower with ticagrelor 90 mg than with ticagrelor 60 
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mg [11]. In the current work, studying a smaller subset of the PEGASUS PK population, we 
could not identify any statistically-significant difference between the two doses. Based on 
less samples and fewer patients, the herein modelled Css,av was generally similar to what was 
observed in the prior MI patients in the main PEGASUS PK population and in the stable 
CAD patients. In the main PEGASUS-TIMI 54 study, the median Css,av was 606 nmol/L with 
the 60 mg dose and 998 nmol/L with the 90 mg dose [11]. In PLATO the median Css,av was 
999 nmol/L with ticagrelor 90 mg [10]. Even if AR-C124910XX and ticagrelor have similar 
potency in inhibiting the P2Y12 receptor [3], including the contribution of active metabolite 
exposure did not provide a better description of the data. This may potentially be explained 
by the fact that the metabolite exposure was approximately one third of the ticagrelor 
exposure and there was high correlation between ticagrelor and metabolite concentration time 
profiles (half-life for the elimination phase was 10.2 hours for ticagrelor and 9.6 hours for the 
metabolite). The current PK/PD evaluation showing high platelet inhibition with both 
ticagrelor 60 mg and 90 mg supports the similar primary efficacy outcome observed for the 
two dosing regimens in PEGASUS-TIMI 54 [2]. Whereas ticagrelor 60 mg on average gives 
close to maximal inhibition, lower doses are expected to translate into platelet inhibition in 
the steeper part of the exposure-response curve, with a higher proportion of patients having 
low inhibition. At lower doses, platelet inhibition is predicted to be overall reduced and more 
variable between patients and show greater peak-to-trough variability in platelet inhibition. 
The variability in the platelet response due to variability in ticagrelor exposure and in the 
sensitivity to ticagrelor treatment is thus more manifested at trough 12 hours after dose than 
at 2 hours post-dose. The PK and platelet inhibition of ticagrelor was assessed in 36 Chinese 
patients with stable CAD [25]. Patients were randomized 1:1:1 to ticagrelor 45, 60 or 90 mg 
(all with low dose ASA). PK and platelet function was measured as PRU using the 
9HULI\1RZDVVD\ at baseline, after single dose, and after 4 days of twice daily dosing. The 
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PRU mean inhibition from baseline over the dosing interval were 64±82% (45 mg), 69±87% 
(60 mg), and 89±94% (90 mg) after 4 days of twice daily dosing. The model predicted (mean 
and 95% prediction interval)  observed mean PRU inhibition over the dosing interval for the 
Chinese study is 73%[CI:56-84] to 89%[CI:79-94] for 45mg, 80%[CI:65-88] to 92%[CI:83-
95] for 60mg and 87%[CI:75-93] to 94%[CI:88-97] for 90mg. Even though in the low range 
for 45 and 60mg the observed data were within the range of the model predicted PRU 
inhibition. Although the optimal degree of platelet inhibition is not fully known, our present 
results indicate that reducing the ticagrelor dose below the currently-used 60 mg and 90 mg 
twice-daily dosing to doses 45 mg or lower, may pose a risk of high platelet reactivity in 
patients with demography similar to those patients included in the present analysis.  
In conclusion, we have characterized the dose-concentration-response relationship between 
ticagrelor and platelet function in patients with a prior MI and stable CAD. Near maximal 
platelet inhibition was consistently seen with both ticagrelor 60 and 90 mg twice-daily 
dosing. At lower doses, platelet inhibition is predicted to be subsequently lower and more 
variable between patients. Similarly, the within-patient fluctuations in platelet inhibition over 
a dosing interval are predicted to increase at lower doses. 
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Table 1 Number of PK and PRU measurements included in modelling  
Study Visit Data Sampling time (hour) Number of 
measurements 
ONSET/OFFSET After first dose PK 0.5,1,2,4,8,24 338+338(5+26) 
  PRU 0,2,8,24 251 
 After last dose PK 0,2,4,8,24,48 310+310(1+3) 
  PRU 0,8,24,48,120,240 357 
PEGASUS After last dose PK 0,2 223+224 (0+0) 
  PRU 0,2 346 
Numbers for PK are Ticagrelor + AR-C124910XX and numbers within parenthesis are for 
data below LOQ. Numbers for PRU data include data from placebo treated patients. 
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Table 2 Final PK/PD model parameter estimates  
Parameter Estimate (RSE%) BSV (%) 
 
(RSE%) 
 
CL/F (L/h) 16.6 (3.6)  24 (8.1) 
Q/F (L/h) 10.4 (4.7) 95 (45) 
Vc/F (L) 156 (4.2)   
Vp/F (L) 55.8 (8.3)   
KTR (h-1) 10.1 (5.8) 54 (7.9) 
Absorption lag time prior MI (h) 0.48 (11)   
Frel 1 FIX  32 (6.6) 
Proportional residual error ticagrelor (%) 32 (4.5)   
CLm/F (L/h) 10.2 (3.0) 28 (9.2) 
Fm 0.22 FIX    
Qm/F (L/h) 4.41 (4.7)   
Vcm/F (L) 7.04 (6.7)   
Vpm/F (L) 42.3 (6.1) 37 (29) 
Proportional residual error metabolite (%) 26 (4.9)   
PRUbaseline ONSET/OFFSET  
PRUbaseline PEGASUS 
311 
261 
(1.9) 
(1.7) 
35 (add*) (8.9) 
EC50 (nmol/L) 116 (5.3) 66 (7.1) 
PRUbaseline-EC50 correlation   0.33 (27) 
Emax (%) 98.5 (0.1) 2.2 (logit*) (6.1) 
Steepness of exposure-response (Ȗ)  1.59 (3.4)   
Additive residual error PRU (at PRU=300)  47.6 (5.6)   
Exponent for PRU error (Į) 0.48 (2.8)   
 
CL/F: ticagrelor apparent clearance, Q/F: ticagrelor inter-compartment clearance, Vc/F: 
ticagrelor central volume of distribution, Vp/F: ticagrelor peripheral volume of distribution, 
KTR: absorption transfer rate constant, Frel: ticagrelor relative bioavailability, CLm/F: 
metabolite apparent clearance, Fm: fraction of ticagrelor metabolised to AR-C124910XX, 
Qm/F: inter-compartment clearance for the metabolite:  Vcm/F: central volume of distribution 
for the metabolite, Vpm: peripheral volume of distribution for the metabolite, PRUbaseline: 
baseline PRU, Emax: maximal platelet inhibition, EC50: ticagrelor concentration at half EmaxȖ
steepness of the concentration-response curve, ĮExponent for PRU residual error. PRU 
residual error was described by a power function: (PRU/300)Į x SDat PRU 300. BSV: between 
subject variability (*standard deviation for PRUbaseline and Emax), RSE%: relative standard 
error (100*SE/mean), The RSE for BSV are reported on the approximate standard deviation 
scale (SE/variance estimate)/2. Emax is derived from the estimated parameter logit(Emax) and 
the RSE is based on numerical integration from the normal distribution of logit(Emax).  
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Figure 1. Visual predictive check of observed and predicted ticagrelor plasma concentrations 
0-24 hours after the first 180 mg dose (upper left panel) and 0-50 hours after the last 90 mg 
steady-state dose (upper right panel) versus time after dose in the ONSET/OFFSET study and 
at pre-dose and 2 hours post-dose after 60 mg (lower left panel) and 90 mg steady-state 
dosing (lower right panel) in the PEGASUS-TIMI 54 platelet function substudy. The solid 
and dashed lines represent the median and the 10th and 90th percentiles of the observations. 
The shaded areas represent 95% confidence intervals of the median and the 10th and 90th 
percentiles predicted by the model. The symbols represent the observed ticagrelor 
concentrations. Dotted line indicates the lower limit of quantification. 
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Figure 2. Visual predictive check of observed and predicted absolute PRU versus 0-24 hours 
after the first ticagrelor 180 mg loading dose (upper left panel) and 0-250 hours after the last 
ticagrelor 90 mg steady-state dose (upper right panel) in the ONSET/OFFSET study and at 
pre-dose and 2 hours post-dose after 60 mg (lower left panel) and 90 mg (lower right panel) 
steady-state dosing in the PEGASUS-TIMI 54 platelet function substudy. The solid and 
dashed lines represent the median and the 10th and 90th percentiles of the observations. The 
shaded areas represent 95% confidence intervals of the median and the 10th and 90th 
percentiles predicted by the model.  The symbols represent observed data. 
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Figure 3. Observed PRU inhibition in ONSET/OFFSET study (red) and PEGASUS-TIMI 54 
platelet function substudy (green), and model predicted median PRU inhibition (black line) 
with 95% prediction interval (shaded area). 
 
  
  
This article is protected by copyright. All rights reserved. 
 
Figure 4. Predicted PRU inhibition dose response at steady state for BID dosing at 2 hours 
post-dose (left) and at trough 12 hours after dose (right) for Ticagrelor 15 ± 90 mg BID 
dosing. Whiskers extend from 5% to the 95% quantile.  
 
 
 
